组蛋白修饰治疗侵袭性 B 细胞淋巴瘤中 MYC 介导的 miR-29 的 HDAC3 和 EZH2 协同沉默。
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
机构信息
Departments of Malignant Hematology and Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33613.
Department of Immunology and Malignant Hematology, Tianjin Cancer Hospital, Tianjin, China.
出版信息
Cancer Cell. 2012 Oct 16;22(4):506-523. doi: 10.1016/j.ccr.2012.09.003.
Abstract
We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 targeting miR-26a, and EZH2 induces MYC via inhibition of the MYC targeting miR-494 to create positive feedback. Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo. These findings define a MYC-mediated miRNA repression mechanism, shed light on MYC lymphomagenesis mechanisms, and reveal promising therapeutic targets for aggressive B-cell malignancies.
摘要
我们研究了 MYC、HDAC3 和 EZH2 对套细胞淋巴瘤和其他与 MYC 相关的淋巴瘤中 miR-29 的转录和表观遗传抑制作用。我们证明 miR-29 被 MYC 通过与 HDAC3 和 EZH2 形成的核心抑制复合物抑制。MYC 通过抑制 EZH2 的靶向 miR-26a 而上调 EZH2，EZH2 通过抑制 MYC 的靶向 miR-494 诱导 MYC，从而产生正反馈。联合抑制 HDAC3 和 EZH2 协同破坏了 MYC-EZH2-miR-29 轴，导致 miR-29 的表达恢复，miR-29 靶向基因下调，体外和体内淋巴瘤生长受到抑制。这些发现定义了一种 MYC 介导的 miRNA 抑制机制，阐明了 MYC 淋巴瘤发生机制，并揭示了侵袭性 B 细胞恶性肿瘤有希望的治疗靶点。
相似文献
1
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.组蛋白修饰治疗侵袭性 B 细胞淋巴瘤中 MYC 介导的 miR-29 的 HDAC3 和 EZH2 协同沉默。
Cancer Cell. 2012 Oct 16;22(4):506-523. doi: 10.1016/j.ccr.2012.09.003.
2
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.破坏 MYC-miRNA-EZH2 环以抑制侵袭性 B 细胞淋巴瘤的存活和克隆性。
Leukemia. 2013 Dec;27(12):2341-50. doi: 10.1038/leu.2013.94. Epub 2013 Mar 29.
3
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma.c-Myc 介导的 microRNA-101 表观遗传沉默导致肝癌中多个通路的失调。
Hepatology. 2014 May;59(5):1850-63. doi: 10.1002/hep.26720. Epub 2014 Mar 27.
4
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.Myc 通过募集组蛋白去乙酰化酶 3 抑制套细胞淋巴瘤和其他非霍奇金 B 细胞淋巴瘤中的 miR-15a/miR-16-1 的表达。
Oncogene. 2012 Jun 14;31(24):3002-3008. doi: 10.1038/onc.2011.470. Epub 2011 Oct 17.
5
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.MYC 通过抑制其负调节因子 miR-26a 来刺激 EZH2 的表达。
Blood. 2008 Nov 15;112(10):4202-12. doi: 10.1182/blood-2008-03-147645. Epub 2008 Aug 19.
6
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.蛋白质精氨酸甲基转移酶5抑制肿瘤抑制性微小RNA，这些微小RNA在侵袭性B细胞淋巴瘤中下调细胞周期蛋白D1和c-MYC的表达。
J Biol Chem. 2020 Jan 31;295(5):1165-1180. doi: 10.1074/jbc.RA119.008742. Epub 2019 Dec 10.
7
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.SOX4与EZH2和HDAC3相互作用，以抑制侵袭性食管癌细胞中的微小RNA-31。
Mol Cancer. 2015 Feb 3;14:24. doi: 10.1186/s12943-014-0284-y.
8
Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.MYC 和 EZH2 的过表达通过表观遗传沉默 MST1 的表达。
Epigenetics. 2014 Apr;9(4):634-43. doi: 10.4161/epi.27957. Epub 2014 Feb 27.
9
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.展示了多梳组基因 EZH2 突变在淋巴瘤发生中的致癌作用的转基因小鼠模型。
Blood. 2014 Jun 19;123(25):3914-24. doi: 10.1182/blood-2012-12-473439. Epub 2014 May 6.
10
Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.小细胞和侵袭性B细胞非霍奇金淋巴瘤中zeste同源物2（EZH2）蛋白的差异表达以及侵袭性B细胞淋巴瘤中p-ERK1/2和MYC对EZH2表达的差异调节。
Mod Pathol. 2016 Sep;29(9):1050-7. doi: 10.1038/modpathol.2016.114. Epub 2016 Jun 10.
引用本文的文献
1
Identification of a chromatin regulator signature and potential candidate drugs for primary open-angle glaucoma.原发性开角型青光眼染色质调节因子特征及潜在候选药物的鉴定
Epigenomics. 2025 Apr;17(6):377-387. doi: 10.1080/17501911.2025.2479420. Epub 2025 Mar 17.
2
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2 germinal center-derived lymphoma.YPEL2调节BRD4-EZH2双重靶向治疗生发中心来源的EZH2淋巴瘤的疗效。
Neoplasia. 2025 Mar;61:101131. doi: 10.1016/j.neo.2025.101131. Epub 2025 Feb 5.
3
Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes.多发性骨髓瘤细胞的免疫逃逸源于miR29b水平低下以及随后蛋白酶体基因的表观遗传沉默。
Biomark Res. 2024 Apr 23;12(1):43. doi: 10.1186/s40364-024-00592-y.
4
The TGFβ2-Snail1-miRNA Circuitry is Critical for the Development of Aggressive Functions in Breast Cancer.TGFβ2-Snail1-miRNA 通路对乳腺癌侵袭功能的发展至关重要。
Clin Transl Med. 2024 Feb;14(2):e1558. doi: 10.1002/ctm2.1558.
5
MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.miRNA 介导的癌症中组蛋白修饰酶的调节：机制和治疗意义。
Biomolecules. 2023 Oct 28;13(11):1590. doi: 10.3390/biom13111590.
6
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.溴结构域和末端结构域（BET）蛋白：生物学功能、疾病和靶向治疗。
Signal Transduct Target Ther. 2023 Nov 6;8(1):420. doi: 10.1038/s41392-023-01647-6.
7
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and /p53 - a Nordic Lymphoma Group study.MYC 蛋白是套细胞淋巴瘤的一个高危因素，可识别形态学、增殖和 /p53 以外的病例——一项北欧淋巴瘤组研究。
Haematologica. 2024 Apr 1;109(4):1171-1183. doi: 10.3324/haematol.2023.283352.
8
Epigenetic targets in B- and T-cell lymphomas: latest developments.B细胞和T细胞淋巴瘤中的表观遗传靶点：最新进展
Ther Adv Hematol. 2023 May 30;14:20406207231173485. doi: 10.1177/20406207231173485. eCollection 2023.
9
Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation.微小RNA在血液系统恶性肿瘤和造血干细胞移植中的临床意义
Cancers (Basel). 2023 May 8;15(9):2658. doi: 10.3390/cancers15092658.
10
The roles of EZH2 in cancer and its inhibitors.EZH2 在癌症中的作用及其抑制剂。
Med Oncol. 2023 May 6;40(6):167. doi: 10.1007/s12032-023-02025-6.
本文引用的文献
1
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.Myc 通过募集组蛋白去乙酰化酶 3 抑制套细胞淋巴瘤和其他非霍奇金 B 细胞淋巴瘤中的 miR-15a/miR-16-1 的表达。
Oncogene. 2012 Jun 14;31(24):3002-3008. doi: 10.1038/onc.2011.470. Epub 2011 Oct 17.
2
DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs.DNA 甲基转移酶通过 microRNAs 调控 BMI1 和 EZH2 来控制干细胞衰老。
PLoS One. 2011 May 10;6(5):e19503. doi: 10.1371/journal.pone.0019503.
3
Role of microRNAs in lymphoid biology and disease.microRNAs 在淋巴生物学和疾病中的作用。
Curr Opin Hematol. 2011 Jul;18(4):266-72. doi: 10.1097/MOH.0b013e3283476012.
4
MYC and aggressive B-cell lymphomas.MYC 与侵袭性 B 细胞淋巴瘤。
Adv Anat Pathol. 2011 May;18(3):219-28. doi: 10.1097/PAP.0b013e3182169948.
5
MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.miR-26a 通过抑制 EZH2 抑制鼻咽癌的细胞生长和肿瘤发生。
Cancer Res. 2011 Jan 1;71(1):225-33. doi: 10.1158/0008-5472.CAN-10-1850.
6
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.KIT 驱动的髓性白血病中的 Sp1/NFkappaB/HDAC/miR-29b 调控网络。
Cancer Cell. 2010 Apr 13;17(4):333-47. doi: 10.1016/j.ccr.2010.03.008.
7
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.微小 RNA 表达谱分析及 miR-29 通过靶向细胞周期蛋白依赖性激酶 6 作为套细胞淋巴瘤的预后标志物和致病因子的鉴定。
Blood. 2010 Apr 1;115(13):2630-9. doi: 10.1182/blood-2009-09-243147. Epub 2010 Jan 19.
8
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.组蛋白甲基转移酶EZH2抑制剂3-去氮杂氮胞苷A与组蛋白去乙酰化酶抑制剂帕比司他联合用于抗人急性髓系白血病细胞的表观遗传治疗。
Blood. 2009 Sep 24;114(13):2733-43. doi: 10.1182/blood-2009-03-213496. Epub 2009 Jul 28.
9
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.治疗性微小RNA递送可抑制小鼠肝癌模型中的肿瘤发生。
Cell. 2009 Jun 12;137(6):1005-17. doi: 10.1016/j.cell.2009.04.021.
10
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.人类癌症中组蛋白H3K27去甲基化酶基因UTX的体细胞突变。
Nat Genet. 2009 May;41(5):521-3. doi: 10.1038/ng.349. Epub 2009 Mar 29.
Zotero 插件